Literature DB >> 15920993

Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease.

Salvatore Santo Signorelli1, Grazia Malaponte, Massimo Libra, Luigi Di Pino, Gabriella Celotta, Valentina Bevelacqua, Marcello Petrina, Giuseppina S Nicotra, Manuela Indelicato, Patrick M Navolanic, Giuseppe Pennisi, Maria Clorinda Mazzarino.   

Abstract

Deregulation of matrix metalloproteinases (MMPs) is an important factor contributing to the development of vascular lesions. Plasma levels and zymographic activities of MMP-2 and MMP-9 were investigated in type II diabetics with (n = 51) or without (n = 42) peripheral artery disease (PAD) and in normal volunteers (n = 23). Plasma MMP-2 levels were higher in type II diabetics with (p < 0.01) or without (p > 0.05) PAD in comparison with normal volunteers. Similarly, type II diabetics with (p < 0.0001) or without (p > 0.05) PAD had higher plasma MMP-9 levels than normal volunteers. Plasma zymographic activities of both MMP-2 and MMP-9 were positively correlated with their plasma levels. Plasma MMP-2 zymographic activity was higher in type II diabetics with PAD than type II diabetics without PAD (p > 0.05). Plasma MMP-9 zymographic activity was higher in type II diabetics with (p < 0.0001) or without (p < 0.0001) PAD in comparision with normal volunteers. Together, these results indicate that increased plasma levels and zymographic activities of MMP-2 and MMP-9 may contribute to PAD in type II diabetics. In particular, plasma MMP-9 may be a useful marker for the development of vascular disease in type II diabetics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920993     DOI: 10.1191/1358863x05vm582oa

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  43 in total

Review 1.  Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine.

Authors:  Eden Avishai; Kristina Yeghiazaryan; Olga Golubnitschaja
Journal:  EPMA J       Date:  2017-03-03       Impact factor: 6.543

2.  Biochemical and Biophysical Cues in Matrix Design for Chronic and Diabetic Wound Treatment.

Authors:  Yun Xiao; Samad Ahadian; Milica Radisic
Journal:  Tissue Eng Part B Rev       Date:  2016-08-19       Impact factor: 6.389

Review 3.  Biomarkers and Genetics in Peripheral Artery Disease.

Authors:  Surovi Hazarika; Brian H Annex
Journal:  Clin Chem       Date:  2016-11-21       Impact factor: 8.327

4.  Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases.

Authors:  B T Hawkins; T F Lundeen; K M Norwood; H L Brooks; R D Egleton
Journal:  Diabetologia       Date:  2006-12-02       Impact factor: 10.122

Review 5.  Adipose extracellular matrix remodelling in obesity and insulin resistance.

Authors:  Tae-Hwa Chun; Li Kang
Journal:  Biochem Pharmacol       Date:  2016-05-12       Impact factor: 5.858

Review 6.  The extracellular matrix and insulin resistance.

Authors:  Ashley S Williams; Li Kang; David H Wasserman
Journal:  Trends Endocrinol Metab       Date:  2015-06-06       Impact factor: 12.015

Review 7.  Matrix metalloproteinases and peripheral arterial disease.

Authors:  Chiara Busti; Emanuela Falcinelli; Stefania Momi; Paolo Gresele
Journal:  Intern Emerg Med       Date:  2009-07-21       Impact factor: 3.397

8.  A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

9.  The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients.

Authors:  Milan Gupta; Hwee Teoh; Mahesh Kajil; Michelle Tsigoulis; Adrian Quan; Manoela Fb Braga; Subodh Verma
Journal:  Exp Clin Cardiol       Date:  2012

10.  Matrix metalloproteinase-2 dysregulation in type 1 diabetes.

Authors:  Kathryn M Thrailkill; Robert C Bunn; Cynthia S Moreau; Gael E Cockrell; Pippa M Simpson; Hannah N Coleman; J Paul Frindik; Stephen F Kemp; John L Fowlkes
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.